The strong revenue beat and sequential growth confirm ANKTIVA's commercial momentum. The fully enrolled pivotal trial de-risks a key regulatory milestone. Traders should monitor the upcoming 10-Q for final numbers and any updates on the BLA submission timeline.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 9 $7.48entry
- T+1 · 7mo ago −2.67%α −2.61% · $7.28
- T+5 · 7mo ago −3.07%α −6.26% · $7.25
- T+20 · 6mo ago +12.03%α +4.46% · $8.38
- T+60 · 4mo ago +19.12%α +8.34% · $8.91
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ImmunityBio reported preliminary Q1 2026 net product revenue of $44.2 million, a 168% year-over-year increase, driven by continued adoption of ANKTIVA. The company also announced full enrollment in its pivotal BCG-naïve NMIBC trial, with a supplemental BLA submission on track for 2026.
Key Financial Metrics
Key Facts
- Preliminary Q1 2026 net product revenue: $44.2 million (168% YoY increase)
- Q1 2026 revenue represents a 15% sequential increase over Q4 2025 ($38.3M)
- Full-year 2025 net product revenue was $113 million, a 700% increase over 2024
- Pivotal BCG-naïve NMIBC CIS trial (QUILT-2.005) is fully enrolled with IDMC confirming adequate statistical power
- Supplemental BLA submission for BCG-naïve NMIBC is on track for 2026
- Cash, cash equivalents, and marketable securities estimated at $380.9 million as of March 31, 2026
Financial Impact
Preliminary Q1 revenue of $44.2M beats consensus of $43.2M and represents a 168% YoY increase
Risk Factors
- Preliminary financials are subject to final adjustments in the upcoming 10-Q
- The company continues to report a net loss, though it narrowed in 2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326110-26-000036 |
| Document: ibrx-2026498xkexhibit991.htm | 0001326110-26-000036 |
| Document: 0001326110-26-000036-index-headers.html | 0001326110-26-000036 |
| Document: 0001326110-26-000036-index.html | 0001326110-26-000036 |
| Document: 0001326110-26-000036.txt | 0001326110-26-000036 |
| 8-K Data (Synthetic) | 0001326110-26-000036 |
Track record
11 reports on IBRX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $8.93 Now $5.98 −33.03% settles Feb 2
- Oct 14, 20264w ago 8-K Bullish 7/10 Entry $10.00 Now $5.98 −40.20% settles Jan 12
- Aug 4, 202614w ago 8-K Neutral 5/10 Entry $6.95 to $8.63 Now $5.98 −13.96% ▲ +24.17% +24.39% vs SPY
- Jul 6, 202619w ago Insider Cluster Neutral 2/10 Entry $8.76 to $9.44 Now $5.98 −31.74% ▲ +7.76% +5.77% vs SPY
- Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $9.44 to $8.52 Now $5.98 −36.65% ▼ −9.75% −12.54% vs SPY
- May 18, 202626w ago 8-K Bullish 5/10 Entry $7.76 to $7.65 Now $5.98 −22.94% ▼ −1.42% −7.71% vs SPY
- Apr 9, 202631w ago 8-K Bullish 8/10 Viewing Entry $7.48 to $8.91 Now $5.98 −20.05% ▲ +19.12% +8.34% vs SPY
- Apr 6, 202632w ago 8-K Neutral 4/10 Entry $7.08 to $9.20 Now $5.98 −15.54% ▲ +29.94% +16.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers